Mirum Pharmaceuticals' Phase 3 EXPAND study of LIVMARLI meets primary endpoint

Mirum Pharmaceuticals said its Phase 3 EXPAND study of LIVMARLI (maralixibat) met its primary endpoint in cholestatic pruritus for patients six months and older with ultra-rare cholestatic liver conditions including biliary atresia, achieving statistical significance across all secondary endpoints. The company announced the topline results in a statement.

Detected & updated continuously · Source: Nebula